HBV and HCV co-infections in HIV positive patients in the "HAART era": New challenges;Coinfecciones por HBV y HCV en pacientes HIV positivos en la "era HAART": Nuevos desafios

Medicina

Volumn 67, Issue 1, 2007, Pages 82-91

  Laufer, Natalia A ^a,b   Quarleri, Jorge F ^b   Bouzas, Maria B ^c   Perez, Hector M ^a   Salomon, Horacio ^b   Cahn, Pedro E ^a  

^a HOSPITAL JUAN A FERNÁNDEZ   (Argentina)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^c HOSPITAL F J MUÑIZ   (Argentina)

Author keywords

Diagnosis; HBV; HCV; HIV; Treatment

Indexed keywords

ADEFOVIR; ALPHA INTERFERON; ANTIVIRUS AGENT; EMTRICITABINE; ENTECAVIR; INTERFERON; LAMIVUDINE; PEGINTERFERON; RIBAVIRIN; TENOFOVIR;

ARTICLE; CHRONIC DISEASE; CLINICAL PROTOCOL; DEVELOPED COUNTRY; DIAGNOSTIC PROCEDURE; DRUG EFFICACY; FATIGUE; FLU LIKE SYNDROME; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEMATOLOGIC DISEASE; HEPATITIS B; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER BIOPSY; LIVER FAILURE; MONOTHERAPY; MORBIDITY; MORTALITY; NONHUMAN; RISK ASSESSMENT; SUPERINFECTION; SURVIVAL; VIRUS GENOME; VIRUS TRANSMISSION;

ADULT; AGED; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ARGENTINA; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; SEROEPIDEMIOLOGIC STUDIES;

EID: 33947715285     PISSN: 00257680     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (76)

1. Pando M, Biglione MM, Toscano MF, et al. Human immunodeficiency virus type 1 and other viral co-infections among young heterosexual men and women in Argentina. Am J Trop Med Hyg. 2004; 71: 153-9.
2. Fainboim H, González J, Fassio E, et al. Prevalence of hepatitis viruses in an anti-human immunodeficiency virus-positive population from Argentina. A multicentre study. J Viral Hepat. 1999; 6: 53-7.
3. Weissenbacher M, Rossi D, Radulich G, et al. High seroprevalence of bloodborne viruses among street-recruited injection drug users from Buenos Aires, Argentina. Clin Infect Dig. 2003; 37 (Suppl 5): S348-52.
4. Picchio GR, Nakatsuno M, Boggiano C, et al. Hepatitis C (HCV) genotype and viral titer distribution among Argentinean hemophilic patients in the presence or absence of human immunodeficiency virus (HIV) co-infection. J Med Virol 1997; 52: 21 9-25.
5. Remesar M, Gamba C, Kuperman S, et al. Antibodies to hepatitis C and other viral markersin multi-transfused patients from Argentina. J Clin Virol 2005; 34 (Suppl 2): S20-6.
6. Gretch DR. Diagnostic tests for hepatitis C. Hepatalogy 1997; 26: 43S-47S.
7. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. U.S. Public Health Service (USPHS) and Infectious Diseases Society of America (IDSA). MMWR Recomm Rep 1999; 48: 1-59, 61-6.
8. Dieterich DT, Purow JM, Rajapaksa R. Activity of combination therapy with interferon alfa-2b plus ribavirin in chronic hepatitis C patients co-infected with HIV. Semin Liver Dis 1999; 19 (Suppl 1): 87-94.
9. McNair AN, Main J, Thomas HC. Interactions of the human immunodeficiency virus and the hepatotropic viruses. Semin Liver Dis 1992; 12: 188-96.
10. Cribier B, Rey D, Schmitt C, Lang JM, Kim A, Stoll-Keller F. High hepatitis C viraemia and impaired antibody response in patients coinfected with HIV. AIDS 1995; 9: 1131-6.
11. Lefrere JJ, Guiramand S, Lefrere F, Mariotti M, Aumont P, Lerable J, Petit JC, Girot R, Morand-Joubert L. Full or partial seroreversion in patients infected by hepatitis C virus. J Infect Dis 1997; 175: 316-22.
12. McHutchison JG, Polito A, Person JL, et al. Assessment of hepatitis C antibody tests in homosexual men with hyperglobulinemia. J Infect Dis 1991; 164: 217-8.
13. Marcellin P, Martinot-Peignoux M, Elias A, et al. Hepatitis C virus (HCV) viremia in human immunodeficiency virus-seronegative and -seropositive. patients with indeterminate HCV recombinant immunoblot assay. J Infect Dis 1994; 170: 433-5.
14. Wang SN, Lok AS. Treatment of hepatitis B: who, when, and how? Arch Intern Med. 2006 Jan 9; 166: 9-12.
15. Bartholomeusz A, Schaefer S. Hepatitis B virus genotypes: comparison of genotyping methods. Rev Med Virol 2004; 14: 3-16.
16. Liu CJ, Kao JH, Chen DS. Therapeutic implications of hepatitis B virus genotypes. Liver Int 2005; 25: 1097-107.
17. Mayerat C, Mantegani A, Frei PC. Does hepatitis B virus (HBV) genotype influence the clinical outcome of HBV infection? J Viral Hepat 1999; 6: 299-304.
18. Sanchez-Tapias JM, Costa J, Mas A, Bruguera M, Rodes J. Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients. Gastroenterology 2002; 123: 1848-56.
19. Franca PH, González JE, Munne MS, et al. Strong association between genotype F and hepatitis B virus (HBV) e antigen-negative variants among HBV-infected argentinean blood donors. J Clin Microbiol 2004; 42: 5015-21.
20. Magnius LO, Norder H. Subtypes, genotypes and molecular epidemiology of the hepatitis B virus as reflected by sequence variability of the S-gene. Intervirologyn 1995; 38: 24-34.
21. Simmonds P, Bukh J, Combet C, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005; 42: 962-73.
22. Simmonds P. Genetic diversity and evolution of hepatitis C virus-15 years on. J Gen Virol. 2004; 85: 3173-88.
23. Quarleri JF, Robertson BH, Mathet VL, et al. Genomic and phylogenetic analysis of hepatitis C virus isolates from argentine patients: a six-year retrospective study. J Clin Microbiol 2000; 38: 4560-8.
24. Goedert JJ; Second Multicenter Hemophilia Cohort Study. Prevalence of conditions associated with human immunodeficiency and hepatitis virus infections among persons with haemophilia, 2001-2003. Haemophilia 2005; 11: 516-28.
25. Arribas J, Gonzalez-Garcia J, Lorenzo A, et al. Single (B or C), dual (BC or BD) and triple (BCD) viral hepatitis in HIV-infected patients in Madrid, Spain. AIDS 2005; 19 1361-5.
26. Bica I, McGovern B, Dhar R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodefi-ciency virus infection. Clin Infect Dis 2001; 32: 492-7.
27. Halpern SD, Ubel PA, Caplan AL. Solid-organ transplantation in HIV-infected patients. N Engl J Med 2002 25; 347: 284-7.
28. Hoofnagle JH. Hepatitis C: the clinical spectrum of disease. Hepatology 1997; 26: 15S-20S.
29. Vallet-Pichard A, Pol S. Natural history and predictors of severity of chronic hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection. J Hepatol 2006; 44: S28-34.
30. Zylberberg H, Pol S. Reciprocal interactions between human immunodeficiency virus and hepatitis C virus infections. Clin Infect Dis 1996; 23: 1117-25.
31. Garcia-Samaniego J, Soriano V, Castilla J, et al. Influence of hepatitis C virus genotypes and HIV infection on histological severity of chronic hepatitis C. The Hepatitis/HIV Spanish Study Group. Am J Gastroenterol 1997; 92: 1130-4.
32. Benhamou Y, Bochet M, Di Martino V, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999; 30: 1054-8.
33. Soto B, Sanchez-Quijano A, Rodrigo L, et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired HCV with an unusually rapid progression to cirrhosis. J Hepatol 1997; 26: 1-5.
34. Bonacini M, Puoti M. Hepatitis C in patients with human immunodeficiency virus infection: diagnosis, natural history, meta-analysis of sexual and vertical transmission, and therapeutic issues. Arch Intern Med 2000; 160: 3365-73.
35. Sabin CA, Telfer P, Phillips AN, Bhagani S, Lee CA. The association between hepatitis C virus genotype and human immunodeficiency virus disease progression in a cohort of hemophilic men. J Infect Dis 1997; 175: 164-8.
36. Eskild A, Magnus P, Petersen G, et al. Hepatitis B antibodies in HIV-infected homosexual men are associated with more rapid progression to AIDS. AIDS 1992; 6: 571-4.
37. Gilson RJ, Hawkins AE, Beecham MR, et al. Interactions between HIV and hepatitis B virus in homosexual men: effects on the natural history of infection. AIDS; 11: 597-606.
38. Gatanaga H, Yasuoka A, Kikuchi Y, Tachikawa N, Oka S. Influence of prior HIV-1 infection on the development of chronic hepatitis B infection. EurJ Clin Microbiol Infect Dis 2000; 19: 237-9.
39. Weller IV, Brown A, Morgan B, et al. Spontaneous loss of HBeAg and the prevalence of HTLV-III/LAV infection in a cohort of homosexual hepatitis B virus carriers and the implications for antiviral therapy. J Hepatol 1986; 3 (Suppl 2): S9-16.
40. Krogsgaard K, Lindhardt BO, Nielson JO, et al. The influence of HTLV-III infection on the natural history of hepatitis B virus infection in male homosexual HBsAg carriers. Hepatology 1987; 7: 37-41.
41. Alberti A, Clumeck N, Collins S, et al. ECC Jury. Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV coinfected patients. J Hepatol 2005; 42: 615-24.
42. Nuñez M, Puoti M, Camino N, Soriano V. Treatment of chronic hepatitis B in the HIV-infected patient: present and future. Clin Infect Dis 2003; 37: 1678-85.
43. Lok AS, McMahon BJ. Chronic hepatitis B: update of recommendations. Hepatology 2004; 39: 857-61.
44. Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States. Clin Gastroenterol Hepatol 2004; 2: 87-106.
45. Khalili M, PR, Interferon therapy of hepatitis B. Clinics in Liver Disease, 1999; 3: 363-87.
46. Di Martino V, Thevenot T, Boyer N, Degos F, Marcellin P. Serum alanine transaminase level is a good predictor of response to interferon alfa therapy for chronic hepatitis B in human immunodeficiency virus-infected patients. Hepatology 2000; 31: 1030-1.
47. Nuñez M, Soriano V. Management of patients co-infected with hepatitis B virus and HIV. Lancet Infect Dis. 2005; 5: 374-82.
48. Lok AS, McMahon BJ; Practice Guidelines Committee, American Association for the Study of Liver Diseases (AASLD). Chronic hepatitis B: update of recommendations. Hepatology 2004; 39: 857-61.
49. Soriano V, Puoti M, Bonacini M, et al. Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel. AIDS 2005; 19: 221-40.
50. a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351: 1206-17.
51. Chan HL, Leung NW, Hui AY, et al. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone. Ann Intern Med 2005; 142: 240-50.
52. Dore GJ, Cooper DA, Barrett C, Goh LE, Thakrar B, Atkins M. Dual efficacy of lamivudine treatment HIV-hepatitis B coinfected paersons in a randomized, controlled study (CAESAR). J Infect Dis 1999; 180: 607-13.
53. Hoff J, Bani-Sadr F, Bassin M, Raffi F. Evaluation of chronic hepatitis B virus infection in co-infected patients receiving lamivudine as component of anti-HIV regimen. Clin Infect Dis 2001; 32: 963-9.
54. Lai CL, Leung N, Teo EK, et al. Telbivudine Phase II Investigator Group. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 2005; 129: 528-36.
55. Bessesen M, Ives D, Condreay L, Lawrence S, Sherman KE. Chronic active hepatitis B exacerbations in human immunodeticiency virus-infected patients following development of resistance to or withdrawal of lamivudine. Clin Infect Dis 1999; 28: 1032-5.
56. Nubling CM, von Wangenheim G, Staszewski S, Lower J. Hepatitis C virus antibody prevalence among human immunodeficiency virus-1-infected individuals: analysis with different test systems. J Med Virol 1994; 44: 49-53.
57. Benhamou Y, Bochet M, Thibault V, et al. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. Lancet 2001; 358: 718-23.
58. Lada O, Benhamou Y, Cahour A, Katlama C, Poynard T, Thibault V. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir. Antivir Ther 2004; 9: 353-63.
59. Peters M, Anderson J, Lynch P, et al. Efficacy of tenofovir disoproxil fumarate is not inferior to adefovir dipivoxil for the treatment of hepatitis B virus in subjects who are coinfected with HIV: results of ACTG A5127. 12th Conference on Retrovirus and Opportunistic Infections; Boston, MA, USA; Feb 22-25, 2005. Abstract 124.
60. Gilleece Y, Nelson M, Clarke A. tenofovir in the treatment of hepatitis B/HIV coinfected individuals. 15th International AIDS Conference; Bangkok, Thailand; July 11-16, 2004. Abstract MoPeB3298.
61. Zimmermann AE, Pizzoferrato T, Bedford J, Morris A, Hoffman R, Braden G. Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. Clin Infect Dis. 2006 Jan 15; 42: 283-90.
62. Buti M, Esteban R. Entecavir, FTC, L-FMAU, LdT and others. J Hepatol 2003; 39: S139-42.
63. Levine S, Hernandez D, Yamanaka G, et al. Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro. Antimicrobial Agents Chemother 2002; 46: 2525-32.
64. Tenney DJ, Levine SM, Rose RE, et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitution in virus already resistant to Lamivudine. Antimicrob Agent Chemother 2004; 48: 3498-507.
65. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment at chronic hepatitis C: a randomised trial. Lancet 2001; 358 (9286): 958-65.
66. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N-Engl J Med. 2002; 347: 975-82.
67. Kontorinis N, Agarwal K, Dieterich DT. Treatment of hepatitis C virus in HIV patients: a' review. AIDS 2005; 19 (Suppl 3): S166-73.
68. Saadeh S, Cammell G, Carey WD, Younossi Z, Barnes D, Easley K. The role of liver biopsy in chronic hepatitis C. Hepatology 2001; 33: 196-200.
69. Soriano V, Puoti M, Sulkowski M, et al. Care of patients with hepatitis C and HIV co-infection. AIDS 2004; 18: 1-12.
70. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 1485-92.
71. Sulkowski MS, Felizarta F, Smith C, et al. Hepatitis Resource Network Clinical Trials Group. Daily versus thrice-weekly interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected persons: a multicenter randomized controlled trial. J Acquir Immune Defic Syndr 2004; 35: 464-72.
72. Zeuzem S, Welsch C, Herrmann E. Pharmacokinetics of peginterferons. Semin Liver Dis 2003; 23 (Suppl 1): 23-8.
73. Chung RT, Andersen J, Volberding P, et al. AIDS Clinical Trials Group A5071 Study Team. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004; 351: 451-9.
74. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. APRICOT Study Group. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351: 438-50.
75. McHutchison JG, Manns M, Patel K, et al; International Hepatitis Interventional Therapy Group. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123: 1061-9.
76. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002; 36: S237-44.